Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03491904 · ClinicalTrials.gov registry record · Phase 1
To Assess the Patients' Ability to Self-Administer Fasinumab
A Phase 1 study of Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT03491904: Completed Phase 1 study of Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by Regeneron Pharmaceuticals.
NCT03491904 is a Phase 1 study of Osteoarthritis, Knee and Osteoarthritis, Hip that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 100 participants, below the 497-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03491904, a Phase 1 study of Osteoarthritis, Knee and Osteoarthritis, Hip, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to demonstrate that the auto-injector(AI) is suitable to be used to administer fasinumab at home by patients or their caregivers, as measured by collecting 12 weeks of actual-use data on the technical performance of the device. The secondary objectives of the study are: * To evaluate the successful injection of fasinumab by patients or their caregivers using the AI in an unsupervised setting * To evaluate patient/caregiver satisfaction with the AI for fasinumab injection in an unsupervised setting * To evaluate exposure in serum for fasinumab administered by patients or their caregivers using an AI in an unsupervised setting, or fasinumab administered by study staff using a PFS that has been used in the phase 3 program * To characterize the safety, tolerability, and immunogenicity of fasinumab administered by patients or their caregivers using an AI in an unsupervised setting, or fasinumab administered by study staff using a PFS that has been used in the phase 3 program
Conditions Studied
Interventions
- DRUG Fasinumab AI
- DRUG Fasinumab PFS
Study Locations (20)
Florida
- Regeneron Research Facility - Ocala
- Regeneron Research Facility - Orlando
- Regeneron Research Facility - Pinellas Park
- Regeneron Research Facility - Port Orange
Arizona
- Regeneron Research Facility - Gilbert
- Regeneron Research Facility - Glendale
Kentucky
- Regeneron Research Facility - Lexington
- Regeneron Research Facility - Lexington
North Carolina
- Regeneron Research Facility - Statesville
- Regeneron Research Facility - Wilmington
Tennessee
- Regeneron Research Facility - Bristol
- Regeneron Research Facility - Knoxville
California
- Regeneron Research Facility - Los Angeles
Colorado
- Regeneron Research Facility - Wheat Ridge
Georgia
- Regeneron Research Facility - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-01-23 |
| Est. Completion | 2020-12-15 |
| Phase | Phase 1 |
What the finished NCT03491904 record still lists
NCT03491904 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 497-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 2 interventions - of which Fasinumab AI is the first listed.
NCT03491904 names 20 study sites across 13 states, led by Florida, Arizona, Kentucky.
Frequently Asked Questions
What is clinical trial NCT03491904 about?
NCT03491904 is a clinical study titled "To Assess the Patients' Ability to Self-Administer Fasinumab". The primary objective is to demonstrate that the auto-injector(AI) is suitable to be used to administer fasinumab at home by patients or their caregivers, as measured by collecting 12 weeks of actual-use data on the technical performance of the device. The secondary objectives of the study are: * ...
What is the current status of trial NCT03491904?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2019-01-23. Estimated completion is 2020-12-15.
What conditions does trial NCT03491904 study?
This clinical trial studies the following conditions: Osteoarthritis, Knee, Osteoarthritis, Hip.
What interventions are being tested in trial NCT03491904?
The interventions under investigation include: Fasinumab AI (DRUG), Fasinumab PFS (DRUG).
Who is sponsoring clinical trial NCT03491904?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03491904 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis, Knee
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03491904's enrollment target sits among peer trials
100 65th of 112 higher than 44 of 112 other Osteoarthritis, Knee trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis, Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
CBD for Knee Osteoarthritis
RECRUITING · Phase 1
-
Oral Steroid Taper After Total Knee Arthroplasty
RECRUITING · Phase 1
-
The Role of Vitamin K on Knee Osteoarthritis Outcomes
RECRUITING · Phase 1
-
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
ACTIVE NOT RECRUITING · Phase 1
-
Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI